Navigation Links
ThromboGenics Announces Private Investors Acquire 8% Stake in the Company

LEUVEN, Belgium, July 30 /PRNewswire-FirstCall/ --

- Shares Acquired From Biggar Limited

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on eye disease, vascular disease and cancer, today announces that a group of private investors based in Belgium have together acquired an 8% stake in the Company. Their stake was purchased from Biggar Limited, a charitable foundation that is ThromboGenics largest shareholder. Biggar now holds a 9.8% stake in ThromboGenics following this transaction, and has informed the company that it intends to remain an important shareholder in ThromboGenics for the long term.

This transaction was managed by Petercam.

Prof. Desire Collen, Chairman and CEO of ThromboGenics, commenting on today's announcement, said: "We are very pleased that we have been able to attract such a group of high net worth individuals to become shareholders in ThromboGenics, particularly given their long term commitment to the Company. We are confident that we will be able to generate significant value for all our shareholders over the next several years based on the exciting prospects for microplasmin in the treatment of back of the eye disease, our other pipeline products, including TB-402 for deep vein thrombosis, as well as the significant potential that we see for TB-403 in the treatment of cancer, which was recently licensed to Roche."

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development by the end of 2008, and TB-403 (Anti-PlGF). ThromboGenics and its development partner BioInvent, have recently signed a license agreement with Roche for TB-403 worth up to EUR500 million plus royalties. A Phase Ib clinical trial with TB-403 has recently begun in patients with late stage cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

For further information please contact:


Chris Buyse, CFO Tel : +32-16-75-13-10

Citigate Dewe Rogerson

Amber Bielecka/Sylvie Berrebi/David Dible Tel.: +44(0)207-638-95-71

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
2. ThromboGenics N.V. - Business Update
3. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
4. ThromboGenics Announces 2007 Full Year Results
5. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
8. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
9. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
10. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
11. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... ... Inc., on being named to Deloitte's 2015 Technology Fast 500 list of the ... manufactures AcceleDent®, a FDA-cleared, Class II medical device that speeds up orthodontic tooth ...
(Date:11/24/2015)... , Nov. 24, 2015 Capricor ... company focused on the discovery, development and commercialization of ... Ph.D., Chief Executive Officer, is scheduled to present at ... 2015 at 10:50 a.m. EST, at The Lotte New ... . . --> ...
(Date:11/24/2015)... 2015  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... president and chief executive officer, will present at the 27 ... New York City . The presentation will ... 2015 at 9:30 a.m. EST. and ... at least 15 minutes prior to the presentation to allow ...
(Date:11/24/2015)... ... 24, 2015 , ... Whitehouse Laboratories is pleased to announce that it has ... be strictly dedicated to basic USP 61, USP 62 and USP 51 testing specific ... complete chemistry and micro testing performed by one supplier. Management has formally ...
Breaking Biology Technology:
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/12/2015)... --  Growing need for low-cost, easy to use, ... the way for use of biochemical sensors for ... clinical, agricultural, environmental, food and defense applications. Presently, ... applications, however, their adoption is increasing in agricultural, ... on improving product quality and growing need to ...
(Date:11/10/2015)... , Nov. 10, 2015 ... biometrics that helps to identify and verify the ... is considered as the secure and accurate method ... of a particular individual because each individual,s signature ... results especially when dynamic signature of an individual ...
Breaking Biology News(10 mins):